Crain’s Cleveland Business (subscription required): Shigemi Matsuyama, associate professor of ophthalmology and visual sciences, outlined his research team’s new $1.5 million grant to test a new drug for retinitis pigmentosa, aiming to prevent blindness and pursue FDA approval, with broader neurodegenerative implications.
